Childhood absence epilepsy: Electro-clinical manifestations, treatment options, and outcome in a tertiary educational center

Aim and Objective: Lung cancer is a highly heterogeneous cancer, due to the significant differences in molecular levels, resulting in different clinical manifestations of lung cancer patients there is a big difference. Including disease characterization, drug response, the risk of recurrence, survival, etc. Method: Clinical patients with lung cancer do not have yet particularly effective treatment options, while patients with lung cancer resistance not only delayed the treatment cycle but also caused strong side effects. Therefore, if we can sum up the abnormalities of functional level from the molecular level, we can scientifically and effectively evaluate the patients' sensitivity to treatment and make the personalized treatment strategies to avoid the side effects caused by over-treatment and improve the prognosis. Result & Conclusion: According to the different sensitivities of lung cancer patients to drug response, this study screened out genes that were significantly associated with drug resistance. The bayes model was used to assess patient resistance.

Download Full-text

Clinical manifestations of hereditary angioedema and a systematic review of treatment options

Laryngoscope Investigative Otolaryngology ◽

10.1002/lio2.555 ◽

2021 ◽

Author(s):

Mattie Rosi‐Schumacher ◽

Sejal J. Shah ◽

Timothy Craig ◽

Neerav Goyal

Keyword(s):

Systematic Review ◽

Hereditary Angioedema ◽

Treatment Options ◽

Clinical Manifestations

Download Full-text

Clinical Management of Hypertension, Inflammation and Thrombosis in Hospitalized COVID-19 Patients: Impact on Survival and Concerns

Journal of Clinical Medicine ◽

10.3390/jcm10051073 ◽

2021 ◽

Vol 10 (5) ◽

pp. 1073

Author(s):

Patricia Martínez-Botía ◽

Ángel Bernardo ◽

Andrea Acebes-Huerta ◽

Alberto Caro ◽

Blanca Leoz ◽

...

Keyword(s):

Arterial Hypertension ◽

Clinical Management ◽

Cox Regression ◽

Angiotensin Receptor Blockers ◽

Treatment Options ◽

Clinical Manifestations ◽

Specific Treatment ◽

Hospitalized Patients ◽

Thrombosis Prophylaxis ◽

The Impact

The most severe clinical manifestations of the Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are due to an unbalanced immune response and a pro-thrombotic hemostatic disturbance, with arterial hypertension or diabetes as acknowledged risk factors. While waiting for a specific treatment, the clinical management of hospitalized patients is still a matter of debate, and the effectiveness of treatments to manage clinical manifestations and comorbidities has been questioned. In this study, we aim to assess the impact of the clinical management of arterial hypertension, inflammation and thrombosis on the survival of COVID-19 patients. The Spanish cohorts included in this observational retrospective study are from HM Hospitales (2035 patients) and from Hospital Universitario Central de Asturias (72 patients). Kaplan Meier survival curves, Cox regression and propensity score matching analyses were employed, considering demographic variables, comorbidities and treatment arms (when opportune) as covariates. The management of arterial hypertension with angiotensin-converting enzyme 2 (ACE2) inhibitors or angiotensin receptor blockers is not detrimental, as was initially reported, and neither was the use of non-steroidal anti-inflammatory drugs (NSAIDs). On the contrary, our analysis shows that the use on itself of corticosteroids is not beneficial. Importantly, the management of COVID-19 patients with low molecular weight heparin (LMWH) as an anticoagulant significantly improves the survival of hospitalized patients. These results delineate the current treatment options under debate, supporting the effectiveness of thrombosis prophylaxis on COVID-19 patients as a first-line treatment without the need for compromising the treatment of comorbidities, while suggesting cautiousness when administering corticosteroids.

Download Full-text

From Rheumatoid Factor to Anti-Citrullinated Protein Antibodies and Anti-Carbamylated Protein Antibodies for Diagnosis and Prognosis Prediction in Patients with Rheumatoid Arthritis

International Journal of Molecular Sciences ◽

10.3390/ijms22020686 ◽

2021 ◽

Vol 22 (2) ◽

pp. 686

Author(s):

Chao-Yi Wu ◽

Huang-Yu Yang ◽

Shue-Fen Luo ◽

Jenn-Haung Lai

Keyword(s):

Rheumatoid Arthritis ◽

Treatment Options ◽

Clinical Manifestations ◽

Bone Destruction ◽

Response To Therapy ◽

Current Evidence ◽

Prognosis Prediction ◽

Diagnosis And Prognosis ◽

Systemic Inflammatory Disease ◽

Citrullinated Protein

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease mainly involving synovial inflammation and articular bone destruction. RA is a heterogeneous disease with diverse clinical presentations, prognoses and therapeutic responses. Following the first discovery of rheumatoid factors (RFs) 80 years ago, the identification of both anti-citrullinated protein antibodies (ACPAs) and anti-carbamylated protein antibodies (anti-CarP Abs) has greatly facilitated approaches toward RA, especially in the fields of early diagnosis and prognosis prediction of the disease. Although these antibodies share many common features and can function synergistically to promote disease progression, they differ mechanistically and have unique clinical relevance. Specifically, these three RA associating auto-antibodies (autoAbs) all precede the development of RA by years. However, while the current evidence suggests a synergic effect of RF and ACPA in predicting the development of RA and an erosive phenotype, controversies exist regarding the additive value of anti-CarP Abs. In the present review, we critically summarize the characteristics of these autoantibodies and focus on their distinct clinical applications in the early identification, clinical manifestations and prognosis prediction of RA. With the advancement of treatment options in the era of biologics, we also discuss the relevance of these autoantibodies in association with RA patient response to therapy.

Download Full-text

Treatment of Heparin-Induced Thrombocytopenia

Annals of Pharmacotherapy ◽

10.1345/aph.1a204 ◽

2002 ◽

Vol 36 (3) ◽

pp. 489-503 ◽

Cited By ~ 40

Author(s):

William E Dager ◽

Richard H White

Keyword(s):

Adverse Reaction ◽

Treatment Options ◽

Clinical Manifestations ◽

Low Molecular Weight ◽

National Library ◽

Severe Adverse Reaction ◽

Heparin Induced Thrombocytopenia ◽

Immune Mediated ◽

Study Selection ◽

Clinical Conditions

OBJECTIVE: To describe heparin-induced thrombocytopenia (HIT or HIT-2), an immune-mediated adverse reaction to heparin or low-molecular-weight heparin. Available treatment options and considerations in developing a therapy approach are discussed. DATA SOURCES: A search of the National Library of Medicine (1992–June 2001) was done to identify pertinent literature. Additional references were reviewed from selected articles. STUDY SELECTION: Articles related to laboratory recognition and treatment options of HIT, including the use of agents in selected clinical conditions, were reviewed and included. CONCLUSIONS: HIT is a rare but potentially severe adverse reaction to heparin that was, until recently, poorly understood and had limited treatment options. Recent advances describing the recognition and clinical manifestations of immune-mediated HIT, including recently available antithrombotic treatment options, have dramatically changed outcomes for patients having this syndrome.

Download Full-text

Management of Plantar Keratodermas

Journal of the American Podiatric Medical Association ◽

10.7547/16-043 ◽

2017 ◽

Vol 107 (5) ◽

pp. 428-435 ◽

Cited By ~ 2

Author(s):

Rebecca M. Porter ◽

Albert A. Bravo ◽

Frances J.D. Smith

Keyword(s):

Gene Therapy ◽

Salicylic Acid ◽

Alternative Treatment ◽

Autosomal Dominant ◽

Treatment Options ◽

Clinical Manifestations ◽

Specific Treatment ◽

Inherited Mutations ◽

Pachyonychia Congenita

Plantar keratodermas can arise due to a variety of genetically inherited mutations. The need to distinguish between different plantar keratoderma disorders is becoming increasingly apparent because there is evidence that they do not respond identically to treatment. Diagnosis can be aided by observation of other clinical manifestations, such as palmar keratoderma, more widespread hyperkeratosis of the epidermis, hair and nail dystrophies, or erythroderma. However, there are frequent cases of plantar keratoderma that occur in isolation. This review focuses on the rare autosomal dominant keratin disorder pachyonychia congenita, which presents with particularly painful plantar keratoderma for which there is no specific treatment. Typically, patients regularly trim/pare/file/grind their calluses and file/grind/clip their nails. Topical agents, including keratolytics (eg, salicylic acid, urea) and moisturizers, can provide limited benefit by softening the skin. For some patients, retinoids help to thin calluses but may lead to increased pain. This finding has stimulated a drive for alternative treatment options, from gene therapy to alternative nongenetic methods that focus on novel findings regarding the pathogenesis of pachyonychia congenita and the function of the underlying genes.

Download Full-text